Am I a Candidate for GLP-1 Weight Loss Treatment?
- The general BMI ranges clinicians often use as a starting reference
- Why weight-related health conditions change the picture
- What a physician evaluation actually involves
- The histories and medications that get reviewed
Candidacy is a physician decision, not a self-assessment
Let us be clear up front. Whether a GLP-1 is right for you is decided by a licensed clinician, not by a number you calculate at home and not by a quiz. A physician looks at the whole picture, weighs benefit against risk, and can say yes, no, or "let us look closer." That is the part that keeps you safe. Everything below helps you understand the inputs to that decision.
BMI is a starting reference point, not a pass or fail
A common reference point in the labeling is a body mass index of 30 or higher, which is the general threshold for obesity. A lower threshold, around 27 or higher, often applies when a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol is also in the picture 2.
Because they raise the stakes of carrying extra weight, and weight management can help address them. A clinician weighs whether the likely benefit to your health outweighs the risks of the medication for you specifically. That calculation is individual, and it is exactly the kind of judgment a licensed physician is trained to make.
What a physician evaluation actually looks like
A GLP-1 evaluation is a real clinical review, not a checkbox. A clinician collects your health history, your current medications, and the relevant numbers, then weighs whether a GLP-1 is appropriate for you. The point of the evaluation is to reach a safe, individual decision, and that includes the freedom to say no.
Your history and medications are part of the decision
| Factor | What a clinician looks at | Why it matters |
|---|---|---|
| Body mass index | At or above 30, or at or above 27 with a weight-related condition, as a general reference | A starting point read in context, never a stand-alone pass or fail |
| Weight-related conditions | Type 2 diabetes, high blood pressure, high cholesterol, sleep apnea | Can shift a borderline case toward treatment |
| Safety review | Product-specific contraindications, pregnancy instructions and other precautions | Clinician checks the actual label and your history |
| Use-with-caution history | Prior pancreatitis, serious digestive disease | Calls for a closer look and a clear monitoring plan |
| Current medications | Insulin, sulfonylureas, oral medicines that need steady absorption | May need coordinating alongside a GLP-1 |
| Your goals and history | What you have tried, what you are aiming for | Shapes the wider plan around the medicine |
The standard worth demanding before anyone prescribes
What should I bring to my evaluation? Your medical and family history, including thyroid cancer, MEN2, and pancreatitis history. A full list of your current medications. Any recent health numbers you have, like blood pressure or recent labs. And your honest goals. The more complete the picture, the better the decision.
Your next three steps
You opened this page wanting to know if you are a candidate. The honest answer is that only a physician can settle that, and the good ones want to do it carefully. Bring your full picture. Let the evaluation do its job.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Sources
- STEP 1 primary report: adults without diabetes received weekly semaglutide 2.4 mg or placebo plus lifestyle intervention for 68 weeks. Trial eligibility and group averages do not determine an individual outcome. Individual results vary. pubmed.ncbi.nlm.nih.gov
- FDA. Wegovy prescribing information, including adult chronic weight-management eligibility. Revised 2026. accessdata.fda.gov